STOCK TITAN
  1. Home
  2. News
  3. NRSN

NeuroSense Therapeutics Ltd - NRSN STOCK NEWS

Welcome to our dedicated news page for NeuroSense Therapeutics (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on NeuroSense Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroSense Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroSense Therapeutics's position in the market.

News
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
Rhea-AI Summary
NeuroSense Therapeutics and Genetika+ collaborate in a precision medicine initiative focusing on Alzheimer's Disease. The partnership aims to enhance drug development by utilizing advanced technology for patient-specific neuronal analysis. NeuroSense's innovative PrimeC therapy targets multiple disease-related pathologies, offering a promising approach to AD treatment. The ongoing Phase 2 clinical trial at Rambam Health Care Campus will evaluate PrimeC's therapeutic potential in mild to moderate AD patients over 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Rhea-AI Summary
NeuroSense Therapeutics presents positive data validating Phase 2b topline readout during an Emerging Science presentation at the American Academy of Neurology Annual Meeting. The PARADIGM study of PrimeC for Amyotrophic Lateral Sclerosis showed positive clinical effects and a trend towards impacting Neurofilament biomarker levels. PrimeC demonstrated safety, tolerability, and a 37% slowing of disease progression in the per-protocol population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
Rhea-AI Summary
NeuroSense Therapeutics announces the presentation of data from the PARADIGM Phase 2 study of PrimeC for Amyotrophic Lateral Sclerosis at the American Academy of Neurology Annual Meeting. The study met primary and secondary endpoints, highlighting positive outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
conferences
News
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
Rhea-AI Summary
NeuroSense Therapeutics (NRSN) announced a securities purchase agreement with a health-care focused institutional investor for the sale of 2,980,000 shares and warrants at $1.50 per share. The offering includes ordinary warrants with an exercise price of $1.50 per share, exercisable immediately and expiring in 5 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
offering
-
News
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
Rhea-AI Summary
NeuroSense collaborates with Lonza to advance neurodegenerative disease treatments by utilizing Neuron-Derived Exosomes. Positive Phase 2b PARADIGM trial results for PrimeC in ALS patients. Lonza's 'Dev-on-Demand' solution offers rapid access to expert scientists and laboratories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
News
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
Rhea-AI Summary
NeuroSense Therapeutics (NRSN) reported positive clinical results from the Phase 2b ALS trial, showing a 37.4% slowing of disease progression in patients treated with PrimeC. Financially, the company saw an increase in research and development expenses but a decrease in general and administrative expenses, with cash of $2.6 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.48%
Tags
earnings
News
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
Rhea-AI Summary
NeuroSense Therapeutics Ltd. reports positive data from the PARADIGM trial of PrimeC for ALS treatment, showing significant effects on quality of life, survival, and disease progression. PrimeC demonstrated a 53% reduction in ALS complications or death risk, with statistically significant results in the ALSFRS-R scale. Neurofilament results expected in Q1 and biomarkers in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.76%
Tags
clinical trial
-
News
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), ensuring continued listing on the Nasdaq Stock Market. The company's CEO, Alon Ben-Noon, expressed the importance of this event as they focus on advancing PrimeC and reporting results from their collaboration with Biogen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
NeuroSense’s (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Rhea-AI Summary
NRSN Announces Positive Phase 2 Clinical Trial Results for ALS Treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
clinical trial
News
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
Rhea-AI Summary
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares a review of important clinical achievements in 2023, including a statistically significant reduction in ALS disease progression in Phase 2b PARADIGM trial. The company anticipates several biomarker study results in 2024 and partnership discussions as it advances its drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
clinical trial
Stock NRSN logo
NeuroSense Therapeutics Ltd

Nasdaq:NRSN

NRSN Rankings

#5063 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NRSN Stock Data

24.96M
10.65M
28.05%
0.91%
0.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Israel
Herzliya

About NRSN

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa